Zydus Lifesciences gets NoC for generic Mesalamine suppositories 1000 mg

27 Oct 2025 Evaluate

Zydus Lifesciences has received Notice of Compliance (NoC) from Health Canada for generic Mesalamine suppositories 1000 mg. Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.

ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 million CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025). 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×